CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

Trial Profile

CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute biphenotypic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Results (n=6) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 According to a Ziopharm Oncology media release, results from this trial were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 01 Jul 2016 Number of treatment arms has been changed from 2 to 1 and the treatment will be administered as a single group assignment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top